The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro

Biology

Thomas Powles¹  Antonio Reverter²  Tim Eisen³  AntonyC. P. Riddick³  SarahJ. Welsh³  GrantD. Stewart³  AnneY. Warren³  RafiaS. Al-Lamki⁴  JohnR. Bradley⁴  NicholasJ. Hudson⁵  FiachC. O’Mahony⁶  Arran Turnbull⁶  SCOTRRCC Collaborative⁶  DavidJ. Harrison⁶ 

[1] Bart’s Cancer Institute, Charterhouse Square, London EC1M 6BE, UK;CSIRO Agriculture and Food, Queensland Bioscience Precinct, St. Lucia, QLD 4067, Australia;Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK;Department of Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 0QQ, UK;School of Agriculture and Food Sciences, University of Queensland, Gatton, QLD 4343, Australia;Scottish Collaboration on Translational Research into Renal Cell Cancer (SCOTRRCC);

关键词: renal cancer;    kidney cancer;    sunitinib;    PHAX;    organ culture;   

DOI  :  10.3390/biology9040074

来源: DOAJ

【 摘 要 】

Anti-angiogenic agents, such as the multi-tyrosine kinase inhibitor sunitinib, are key first line therapies for metastatic clear cell renal cell carcinoma (ccRCC), but their mechanism of action is not fully understood. Here, we take steps towards validating a computational prediction based on differential transcriptome network analysis that phosphorylated adapter RNA export protein (PHAX) is associated with sunitinib drug treatment. The regulatory impact factor differential network algorithm run on patient tissue samples suggests PHAX is likely an important regulator through changes in genome-wide network connectivity. Immunofluorescence staining of patient tumours showed strong localisation of PHAX to the microvasculature consistent with the anti-angiogenic effect of sunitinib. In normal kidney tissue, PHAX protein abundance was low but increased with tumour grade (G1 vs. G3/4; p < 0.01), consistent with a possible role in cancer progression. In organ culture, ccRCC cells had higher levels of PHAX protein expression than normal kidney cells, and sunitinib increased PHAX protein expression in a dose dependent manner (untreated vs. 100 µM; p < 0.05). PHAX knockdown in a ccRCC organ culture model impacted the ability of sunitinib to cause cancer cell death (p < 0.0001 untreated vs. treated), suggesting a role for PHAX in mediating the efficacy of sunitinib.

【 授权许可】

Unknown